Fact CheckerSign in

NCT05446220Completed

Twelve-year Follow-up on the Treatment of Obese Pregnant Women (TOP) Study

Source: ClinicalTrials.gov · Last updated 21 Nov 2025

Brief summary (registry, in English)

The participant (both mother and child) in the initial TOP study will be invited to a follow-up study to evaluate the effect of life style intervention during pregnancy on both mother and their offspring 12 years after the intervention. The study will contribute to understanding the transfer of obesity between generations and how to treat as well as prevent obesity.

Status (registry)
Completed
Study type
Interventional
Enrollment
497 (actual)
First submitted
1 Jul 2022
Start date
5 Jan 2023
Primary completion date
26 Sept 2025
Lead sponsor
Steno Diabetes Center Copenhagen
Diseases
Obesity
NCT number
NCT05446220

What you commit to

  • Study type: Interventional
  • Participants enrolled: 497
  • From 5 Jan 2023 to the primary completion date, 26 Sept 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • There are no exclusion criteria as the potential study population has already been selected at the baseline study in 2009-2012

Who the study is looking for

  • Participants/mothers in the initial TOP study will be invited with their offspring born following the pregnancy during the initial study to the 12-year follow-up study

Age in the registry: 12 years to 60 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Steno Diabetes Center Copenhagen
Coordinator of this site? Confirm its status
HerlevDenmarkUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.